Evidence map›Paper›PMID 35117332›Full record

ReviewTranslational cancer research2020

Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy.

Yan Yang, Jing Zhou, Cong Cao, Panpan Cai, Xinxuan Wang, Chun Chang, Jingxuan Wang, Qingyuan Zhang

Abstract readReview
In one paragraph

Review in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yan YangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Jing ZhouDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Cong CaoDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Panpan CaiDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Xinxuan WangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Chun ChangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Jingxuan WangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Qingyuan ZhangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B-cell non-Hodgkin's lymphoma (B-NHL) is a lymphoproliferative disorder that affects B lymphocytes. Chimeric antigen receptor (CAR) T-cell immunotherapy is a new type of immunotherapy that uses genetic engineering techniques to modify and expand the patient's autoimmune cells

Indexed as

B-cell lymphomaCAR-Tcombination therapyimmunotherapy

Identifiers

PMID35117332
PMCPMC8798430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.